Spotlight Therapeutics

Spotlight Therapeutics

Edit info

  • Founded: 2017
  • Location: Hayward, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Immuno-oncology
  • Drug types: ONC, HEM, OPH
  • Lead product: Undisclosed
  • Funding: $36.5M B Mar 2022; $30M A Nov 2020; $7.3M as of Jan 2019
  • Investors: GV


spotlighttx.com


Drug notes:

Undisclosed RD HSC-mediated diseases, hemoglobinopathies; undisclosed RD ophthalmic diseases

About:

Spotlight Therapeutics is developing engineered RiboNucleoProteins (eRNPs) to enhance the delivery of CRISPR-based therapeutics. To unlock the full potential of in vivo gene editing therapies, the biomolecules must be delivered to the correct tissue successfully. Using their eRNP platform, Spotlight is exploiting the high modularity of eRNPs to create fit-for-purpose molecules by adding or substituting protein domains on Cas nucleases to enable specific-functionalities such as adenine or cytosine base editing. To attain specificity, Spotlight is developing bioconjugation tools to fuse eRNPs to cell-targeting moieties such as antibodies enabling cell-selective editing. Initially, Spotlight is applying eRNPs to address ophthalmic diseases.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com